Treatment Use of 3,4-Diaminopyridine

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

NCT02012933 ·Status: NO_LONGER_AVAILABLE

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

NCT01825395 ·Status: APPROVED_FOR_MARKETING

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

NCT02090725 ·Status: TERMINATED ·Phase: PHASE2

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

NCT01378546 ·Status: NO_LONGER_AVAILABLE

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

NCT00704925 ·Status: NO_LONGER_AVAILABLE

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

NCT00994916 ·Status: NO_LONGER_AVAILABLE

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I

NCT00439218 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

NCT01645787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

NCT04094948 ·Status: WITHDRAWN ·Phase: PHASE2

Dimethyl Fumarate in Adrenomyeloneuropathy

NCT06513533 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

NCT00439569 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy

NCT00481013 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy

NCT01942590 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

NCT04273737 ·Status: TERMINATED ·Phase: PHASE4

4-Aminopyridine in Episodic Ataxia Type 2

NCT01543750 ·Status: WITHDRAWN ·Phase: PHASE2

Mecamylamine for Autonomic Dysreflexia Prophylaxis

NCT03914677 ·Status: UNKNOWN ·Phase: PHASE4

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720 ·Status: APPROVED_FOR_MARKETING

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

NCT01468350 ·Status: COMPLETED ·Phase: PHASE1

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

NCT02656160 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT00041717 ·Status: COMPLETED ·Phase: PHASE3

Valproate and Levocarnitine in Children With Spinal Muscular Atrophy

NCT01671384 ·Status: UNKNOWN ·Phase: PHASE3

Phenylbutyrate Therapy for Maple Syrup Urine Disease

NCT01529060 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

NCT00140712 ·Status: COMPLETED ·Phase: PHASE1

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

NCT01401257 ·Status: COMPLETED ·Phase: PHASE2